88
Participants
Start Date
November 30, 2015
Primary Completion Date
April 14, 2022
Study Completion Date
April 14, 2022
Colesevelam
Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Clonidine
Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Placebo
Placebo will be identical in appearance to the active drug.
Mayo Clinic Rochester, Rochester
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Center for Research Resources (NCRR)
NIH
Mayo Clinic
OTHER